Roche (RHHBY) said that it has received CE Mark approval for the VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx, enabling the identification of metastatic breast cancer patients with low HER2 expression who may benefit from ENHERTU...

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algorithms will be deployed on Roche's...

Roche’s navify Digital Pathology software platform now offers Ibex’s Artificial Intelligence (AI) algorithms to support clinicians in the diagnosis of breast and prostate cancer. Roche and Ibex cloud-based digital...

HER2 IHC testing in the wake of the 2023 HER2 Breast Guideline Update Clinical Value, Classification & Scoring and the impact of the ASCO-CAP 2023 HER2 Breast Testing Guideline Update Over the past several months, the HER2/neu IHC...

Roche Lab Leaders announces new webinar for September. 07 September, 2023 12pm EDT - 9am PDT - 6pm CET  REGISTER NOW Technological advances in digital and computational pathology open new avenues for personalized healthcare solutions that...

ETH Zurich and Roche are joining forces in Basel to advance the development of new methods that facilitate the search for medicines. Together, they will train specialists for the biomedical challenges of our time. ETH Zurich and Roche...